GANX (STOCKS)
Gain Therapeutics, Inc. Common Stock
$1.760100
+0.080100 (+4.77%)
Prev close: $1.680000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Gene C. Mack
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $74.64M
- Employees
- 25
- P/E (TTM)
- -2.97
- P/B (TTM)
- 5.31
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.13 | $-0.14 | +0.0103 | +7.34% |
|
Dec 2025 (Q4)
|
$-0.11 | $-0.15 | +0.0379 | +25.63% |
|
Sep 2025 (Q3)
|
$-0.15 | $-0.15 | +0.0030 | +1.96% |
|
Jun 2025 (Q2)
|
$-0.19 | $-0.17 | -0.0183 | -10.66% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $19.69M |
| Research and Development | $10.72M |
| Other Operating Expenses | $8.98M |
| Operating Income/Loss | -$19.69M |
| Income/Loss From Continuing Operations After Tax | -$21.24M |
| Income/Loss From Continuing Operations Before Tax | -$20.30M |
| Income Tax Expense/Benefit | $943.68K |
| Net Income/Loss | -$21.24M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$21.24M |
| Net Income/Loss Available To Common Stockholders, Basic | -$21.24M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.58 |
| Diluted Earnings Per Share | -$0.58 |
| Basic Average Shares | 109,186,735 |
| Diluted Average Shares | 109,186,735 |
| Assets | $18.74M |
| Current Assets | $18.22M |
| Noncurrent Assets | $516.70K |
| Fixed Assets | $54.44K |
| Other Non-current Assets | $462.26K |
| Liabilities | $4.73M |
| Current Liabilities | $3.89M |
| Accounts Payable | $1.52M |
| Other Current Liabilities | $2.37M |
| Noncurrent Liabilities | $844.91K |
| Long-term Debt | $373.55K |
| Other Non-current Liabilities | $471.37K |
| Equity | $14.01M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $14.01M |
| Liabilities And Equity | $18.74M |
| Net Cash Flow From Operating Activities | -$19.37M |
| Net Cash Flow From Operating Activities, Continuing | -$19.37M |
| Net Cash Flow From Investing Activities | -$7.47M |
| Net Cash Flow From Investing Activities, Continuing | -$7.08M |
| Net Cash Flow From Financing Activities | $26.46M |
| Net Cash Flow From Financing Activities, Continuing | $26.46M |
| Exchange Gains/Losses | $389.09K |
| Net Cash Flow | -$389.09K |
| Net Cash Flow, Continuing | -$778.17K |
| Comprehensive Income/Loss | -$20.12M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$20.12M |
| Other Comprehensive Income/Loss | -$9.98M |
| Other Comprehensive Income/Loss Attributable To Parent | $1.12M |